# Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

> **NCT00284752** · PHASE2 · COMPLETED · sponsor: **Kaiser Permanente** · enrollment: 56 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT00284752
- **Lead sponsor:** Kaiser Permanente
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-10
- **Final completion:** 2011-12
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2012-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284752, "Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00284752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*